This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "myelosuppression#Multilineage Peripheral Cytopenias"). Conforming nodes should substitute the disorder-specific cytotoxic driver (the particular antineoplastic agent or radiation exposure) and may specialize the cytopenia node to a predominant lineage (e.g. irinotecan/neutropenia-predominant, carboplatin/ thrombocytopenia-predominant) while preserving the conserved HSPC-injury → marrow-suppression → cytopenia → complication chain. The key conformance / consequence target is "myelosuppression#Multilineage Peripheral Cytopenias".
Vascularized human bone-marrow-on-chip myelotoxicity model
ORGAN ON CHIP
Two-channel human bone-marrow microphysiological system that co-cultures CD34+ hematopoietic cells with bone-marrow-derived stromal cells in a fibrin gel beside a perfused, endothelium-lined vascular channel. The system supports multilineage myeloerythroid development and reproduces marrow injury and recovery after clinically relevant chemotherapeutic-drug and ionizing-radiation exposures.
Models:
Cytotoxic Insult to Proliferating Hematopoietic Progenitors, Bone Marrow Hematopoietic Suppression
Scope is limited to the two marrow-level mechanisms directly demonstrated in the publication. The model is not linked to peripheral cytopenias or their clinical complications because those downstream outcomes were not measured on chip.
Cytotoxic Insult to Proliferating Hematopoietic Progenitors
trigger
The conserved initiating lesion is cytotoxic damage to the rapidly dividing hematopoietic stem and progenitor cells (HSPCs) of the bone marrow. Because antiproliferative chemotherapy and radiation are not selective for tumor cells, the highly proliferative marrow compartment is collaterally injured, triggering progenitor apoptosis and cell-cycle arrest regardless of the specific agent involved.
Downstream
-
Bone Marrow Hematopoietic Suppression
Progenitor injury and apoptosis reduce the marrow's capacity to sustain hematopoiesis.
Bone Marrow Hematopoietic Suppression
central effector
Loss of functional progenitors and acute injury to marrow cellularity and the supporting vascular niche suppress hematopoietic output. This is the central effector step: the marrow can no longer replace circulating blood cells at the normal rate, and the deficit becomes the dose-limiting toxicity of the cytotoxic regimen.
Downstream
-
Multilineage Peripheral Cytopenias
Reduced marrow output lowers the numbers of mature blood cells released to the periphery across multiple lineages.
Multilineage Peripheral Cytopenias
effector
Suppressed marrow output reduces the mature blood cells reaching the circulation, producing the multilineage cytopenias that define myelosuppression: neutropenia, anemia, and thrombocytopenia (with lymphopenia in some regimens). This is the key conformance target of the module; conforming disorder nodes may specialize it to the lineage that predominates for a given agent.
Downstream
-
Cytopenia-Related Clinical Complications
Each cytopenia drives its characteristic clinical complication.